About Anthos Therapeutics
Anthos Therapeutics is a company based in Cambridge (United States) founded in 2019 by Paris Panayiotopoulos and Jonathan Freeman was acquired by Novartis in February 2025. It operates as a HealthTech. Anthos Therapeutics has raised $250 million across 1 funding round from investors including Novartis and Blackstone. The company has 14 employees as of December 31, 2023. Anthos Therapeutics offers products and services including Abelacimab. Anthos Therapeutics operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others.
- Headquarter Cambridge, United States
- Employees 14 as on 31 Dec, 2023
- Founders Paris Panayiotopoulos, Jonathan Freeman
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Anthos Therapeutics
Anthos Therapeutics offers a comprehensive portfolio of products and services, including Abelacimab.
Abelacimab is developed as a novel anticoagulant therapy.
People of Anthos Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Anthos Therapeutics
Anthos Therapeutics has successfully raised a total of $250M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $250 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Anthos Therapeutics
Anthos Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis and Blackstone.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked | |
|
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
Locked | Locked | Locked |
Investor details for Anthos Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anthos Therapeutics
Investment portfolio details for Anthos Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Anthos Therapeutics
Detailed financials for Anthos Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anthos Therapeutics Comparisons
Peer comparison for Anthos Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anthos Therapeutics
Anthos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| Locked | Locked | Locked |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| Locked | Locked | Locked |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for retinal diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Antibody-based drugs for primary myopathies are developed and targeted.
|
Detailed competitors of Anthos Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anthos Therapeutics
Complete news archive for Anthos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anthos Therapeutics
Anthos Therapeutics was founded in 2019.
Anthos Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Bill Meury is the current CEO of Anthos Therapeutics.
Anthos Therapeutics is a funded company, having raised a total of $250M across 1 funding round to date.
As of Dec 31, 2023, the latest employee count at Anthos Therapeutics is 14.
Anthos Therapeutics is dedicated to addressing unmet medical needs in the field of anticoagulation. The company is engaged in the development of innovative therapies, particularly targeting Factor XI with their investigational drug Abelacimab. Their work is centered on areas such as atrial fibrillation and cancer-associated thrombosis, aiming to reduce the risk of bleeding compared to traditional treatments. Solutions are being developed to improve patient outcomes in cardiovascular and thrombotic conditions across global healthcare sectors.
Anthos Therapeutics's top competitors include argenx, Zai Lab and Kodiak Sciences.
Anthos Therapeutics offers Abelacimab.
Anthos Therapeutics has 2 investors. Key investors include Novartis, and Blackstone.